Surveillance of a recently switched non-prescription medicine (diclofenac) using a pharmacy-based approach

Pharmacoepidemiology and Drug Safety

Volumn 9, Issue 3, 2000, Pages 207-214

  Gauld, Natalie J ^a   Shaw, John P ^a,b   Emmerton, Lynne M ^a   Pethica, B Damian ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Diversity New Zealand Ltd   (New Zealand)

Author keywords

Community pharmacies; Diclofenac; New Zealand; Non prescription medicines; NSAID; Postmarketing surveillance; Reclassified medicines

Indexed keywords

DICLOFENAC POTASSIUM; NON PRESCRIPTION DRUG;

ADVERSE DRUG REACTION; ARTICLE; BREATHING DISORDER; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; FATIGUE; GASTROINTESTINAL TOXICITY; METHODOLOGY; NAUSEA; NEW ZEALAND; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SKIN TOXICITY; STATISTICS; UROGENITAL TRACT DISEASE; VERTIGO;

EID: 0033926459     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1557(200005/06)9:3<207::AID-PDS483>3.0.CO;2-S     Document Type: Article

References (26)

1. Blenkinsopp A, Bradley C. Patients, society, and the increase in self-medication. BMJ 1996; 312: 629-632.
2. Bradley C, Bond CM. Increasing the number of drugs available over-the-counter: arguments for and against. Br J Gen Pract 1995; 45: 553-556.
3. Gossel TA. Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther 1991; 13: 200-215.
4. Ryan M, Yule B. Switching drugs fro prescription-only to over-the-counter availability: Economicefits in the United Kingdom. Health Policy 1990; 16: 233-239.
5. Smith MC. Prescription to OTC switches: Reflections and projections. Drug Topics 1998; 142(14): 70-79.
6. Barber N. Drugs: from prescription only to pharmacy only. BMJ 1993; 307: 640.
7. Volans G. Monitoring the safety of over the counter drugs. BMJ 1987; 295: 797-798.
8. Schmid B. The safety assessment of over-the-counter products. Arch Toxicol 1995; 17: 305-311.
9. Chaplin S, Blenkinsopp A. Clinical trials in community pharmacies: Too little is known about over-the-counter drugs. BMJ 1992; 304: 63-64.
10. 2 receptor antagonists safe over-the-counter drugs? BMJ 1994; 309: 493-494.
11. Gore MR, Thomas J. Nonprescription informational services in pharmacies and alternative stores: Implications for a third class of drug. J Soc Admin Pharm 1995; 12: 86-89.
12. Hawker G. Prescribing non-steroidal anti-inflammatory drugs - what's new? J Rheumatol 1997; 24: 243-245.
13. DeArmond B, Francisco CA, Lin J-S, et al. Safety profile of over-the-counter naproxen sodium. Clin Ther 1995; 517: 587-601.
14. Lanza FL, Codispoti JR, Nelson EB. An endoscopie comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998; 93: 1020-1023.
15. Emmerton LM, shaw JP, Tucker IG. Pharmacy-based surveillance of Cataflam® (diclofenac potassium): A pilot project. NZ Pharm 1995; 15(1): 22-26.
16. Henry DA, Sutherland D, Francis L, Newcastle Retail Pharmacy Research Group. The use of non-prescription salbutamol by asthmatic patients in the Hunter valley, New South Wales. Med J Aust 1989; 150: 22-26.
17. 2-agonist inhalers and undertreatment of asthma. BMJ 1993; 306: 1514-1518.
18. Nykamp D, Barnett CW, Hooper C. Risk of adverse drug events related to ibuprofen use in a community sample. J Pharm Technol 1994; 10: 110-114.
19. Brånstad JO, Kamil I, Lilja J, Sjoblom M. When topical hydrocortisone became an OTC drug in Sweden - a study of the users and their information sources. Soc Sci Med 1994; 39: 207-212.
20. Shaw JP, Ferry DG, Pethica BD, Brenner D, Tucker IG. Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies. Tobacco Control 1998; 7(2): 161-167.
21. Sift R, Van Staa T-P, Abenhaim L, Ebner D. A study of the utilisation of non-steroidal anti-inflammatory drugs using a pharmacy-based approach. Pharmacoepidemiol Drug Safe 1995; 4: 225-230.
22. Noyelle R, Crossland D, Pickvance N. Ibuprofen, aspirin and paracetamol compared in a community pharmacy. Pharm J 1987; 238: 561-564.
23. Quick J, Blenkinsopp A. A community pharmacy study to compare the control of hay fever symptoms by astemizole 10 mg and terfenadine 120 mg. Pharm J 1991; 246: 272-275.
24. Sonderskov J, Olsen J, Schroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997; 145: 309-318.
25. Cantrill JA, Vaezi L, Nicolson M, Noyce PR. A study to explore the feasibility of using a health diary to monitor therapeutic outcomes from over-the-counter medicines. J Soc Admin Pharm 1995; 12: 190-197.
26. Bond CM, Bradley C. Over-the-counter drugs. The interface between the community pharmacist and patients. BMJ 1996; 312: 758-760.